GSK discontinued the GSK2251052 trials due to the identification of microbiological findings of resistance in few patients in the Phase 2b trial designed to treat complicated urinary tract infections (cUTI).
After conducting additional pre-clinical research and assessing various options, GSK has decided to halt the development of GSK2251052 and return all rights to Anacor.
In July 2010, Anacor licensed GSK2251052 to GSK. Presently both the companies are working together to move GSK2251052 back to Anacor.
According to the companies’ amended R&D collaboration in September 2011, GSK is funding Anacor’s research activities in tuberculosis.